AME Company for Medical Supplies posted a 26% rise in 2022 net profit to SAR 26.7 million, from SAR 21.2 million a year earlier.
| Item | 2021 | 2022 | Change |
|---|---|---|---|
| Revenues | 151.39 | 193.17 | 27.6 % |
| Gross Income | 69.55 | 90.28 | 29.8 % |
| Operating Income | 28.96 | 29.98 | 3.5 % |
| Net Income | 21.22 | 26.68 | 25.7 % |
| Average Shares | 7.00 | 7.00 | - |
| Earnings Per Share before unusual items (Riyals) | 3.67 | 3.81 | 3.9 % |
| EPS (Riyal) | 3.03 | 3.81 | 25.7 % |
The profit growth was driven by an increase of SAR 41.78 million year-on-year (YoY) in net revenue for 2022 (net sales proceeds), as well as a rise of SAR 33.8 million and SAR 8 million in the sales of in medical supplies and devices, respectively.
This surge resulted from the company’s acquisition of a larger market share thanks to its participation in local and international conferences, along with more effort to advertise and market its products.
| Item | H2 2021 | H2 2022 | Change |
|---|---|---|---|
| Revenues | 81.60 | 84.82 | 3.9 % |
| Gross Income | 37.54 | 41.42 | 10.3 % |
| Operating Income | 15.70 | 12.72 | (19.0 %) |
| Net Income | 13.72 | 11.31 | (17.6 %) |
| Average Shares | 7.00 | 7.00 | - |
| Earnings Per Share before unusual items (Riyal) | 1.98 | 1.62 | (18.5 %) |
| EPS (Riyal) | 1.96 | 1.62 | (17.6 %) |
| Item | H1 2022 | H2 2022 | Change |
|---|---|---|---|
| Revenues | 108.35 | 84.82 | (21.7 %) |
| Gross Income | 48.86 | 41.42 | (15.2 %) |
| Operating Income | 17.25 | 12.72 | (26.3 %) |
| Net Income | 15.38 | 11.31 | (26.5 %) |
| Average Shares | 7.00 | 7.00 | - |
| Earnings Per Share before unusual items (Riyal) | 2.20 | 1.62 | (26.5 %) |
| EPS (Riyal) | 2.20 | 1.62 | (26.5 %) |
Total shareholders’ equity, no minority interest, rose to SAR 107.3 million as of Dec. 31, 2022, compared to SAR 93.4 million in the year-earlier period.
Be the first to comment
Argaam Investment Company has updated the Privacy Policy of its services and digital platforms. Know more about our Privacy Policy here.
Argaam uses cookies to personalize content, to provide social media features and analyze traffic, that we might also share with third parties. You consent to our cookies if you use this website
Comments Analysis: